US-based clinical-stage biotechnology company Vyriad will collaborate with Imanis Life Sciences to develop in-vitro and in-vivo theranostic tests to predict a cancer patient’s responsiveness to Vyriad’s oncolytic virus therapeutics.
Under the agreement, Imanis will use its patented virus technology to develop and preclinically attest a companion diagnostic test which will be designed to predict cancer patient’s clinical response to oncolytic virotherapy.
Vyriad will select one or two test formats in its clinical trials to further evaluate the predictive power of the tests.
It is planning to pursue clinical validation and regulatory approval for the tests to be applied in human and animal.
After being approved, Imanis will grant Vyriad a nonexclusive license to use the companion diagnostic tests for the development of its patented oncolytic viruses derived from the company’s vesicular stomatitis virus (VSV), measles virus, or other Vyriad platforms.
Vyriad CEO Stephen Russell said: “We are excited to initiate this collaboration with Imanis Life Sciences for the development of theranostic tests that will help us to streamline patient selection and maximise response rates in Vyriad-sponsored oncolytic virotherapy clinical trials.
“For the first time, we will be able to focus our efforts on those patients with a higher probability of deriving clinical benefit from our drugs while avoiding treating patients that are not likely to respond to them.
“We strongly expect that pairing our oncolytic virotherapies with theranostic tests being developed in this collaboration will greatly accelerate the pathway to FDA marketing approval for our oncolytic virotherapy products.”
Vyriad’s theranostic tests use recombinant vesicular stomatitis viruses to release theranostically informative reporter genes and are permitted to be used as diagnostic reagents in the hospital.